Advertisement
Advertisement
U.S. markets open in 7 hours 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Applied Molecular Transport Inc. (AMTI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0100-0.1100 (-9.82%)
At close: 04:00PM EDT
1.0300 +0.02 (+1.98%)
After hours: 04:09PM EDT
Advertisement

Applied Molecular Transport Inc.

450 East Jamie Court
South San Francisco, CA 94080
United States
650 392 0420
https://www.appliedmt.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees125

Key Executives

NameTitlePayExercisedYear Born
Mr. Graham K. CooperExec. Chairman55kN/A1970
Dr. Tahir Mahmood Ph.D.Co-Founder, CEO & Director609.12kN/A1975
Mr. Shawn M. CrossPres & COO588.54k255.09k1968
Dr. Randall Mrsny Ph.D.Co-Founder & Director613.3kN/A1955
Mr. Brandon HantsChief Financial Officer469.67kN/A1977
Dr. Bittoo Kanwar M.D.Chief Medical Officer625.5k1.05M1976
Mr. Douglas A. Rich M.B.A, M.B.A.Chief Technical OfficerN/AN/A1969
Mr. Andrew H. ChangHead of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Earl M. DouglasExec. VP & Gen. CounselN/AN/A1963
Dr. Andy Whitney Ph.D.Sr. VP of Research & Translational ScienceN/AN/A1961
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Corporate Governance

Applied Molecular Transport Inc.’s ISS Governance QualityScore as of September 1, 2022 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement